Meeting
2013 ASCO Annual Meeting
An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
Authors
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA
F. Stephen Hodi , Christine Baudelet , Allen C. Chen , Jeffrey S. Weber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01783938
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS9107^)
DOI
10.1200/jco.2013.31.15_suppl.tps9107
Abstract #
TPS9107^
Poster Bd #
54D
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
First Author: Dirk Schadendorf
Poster
2018 ASCO Annual Meeting
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).
First Author: Ari M. Vanderwalde
Poster
2015 ASCO Annual Meeting
A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.
First Author: Kim Allyson Margolin
Poster
2013 ASCO Annual Meeting
An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).
First Author: Jeffrey Alan Sosman